MDB Capital questions whether the FDA will heed the advice of the advisory panel on Dendreon (DNDN)
Tweet Send to a Friend
MDB Capital comments on Dendreon Corp. (Nasdaq: DNDN), questioning whether the FDA will heed the advice of the advisory ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
